Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization

@article{Webb2020EthicallyAC,
  title={Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization},
  author={Jamie Webb and Lesha D. Shah and Holly Fernandez Lynch},
  journal={The American Journal of Bioethics},
  year={2020},
  volume={20},
  pages={17 - 4}
}
Abstract Allocating access to unapproved COVID-19 drugs available via Pre-Approval Access pathways or Emergency Use Authorization raises unique challenges at the intersection of clinical care and research. In conditions of scarcity, prioritization approaches should minimize harm, maximize benefit, and promote fairness. To promote continued data collection, patients seeking access to unproven COVID-19 drugs should receive lower priority for allocation when they decline to participate in clinical… 

Ethical Dimensions of Public Health Actions and Policies With Special Focus on COVID-19

This article discusses how preexisting ethical standards were challenged by COVID-19 as well as how monitoring the consistent application of ethical standards during the medical trials of new medications, vaccines, or unproven medical interventions is also a critical issue.

Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research

The authors provide their views on the legal, ethical, and clinical ramifications of restricting patient access to COVID-19 drugs and vaccines that have been granted emergency use authorization by the U.S. Food and Drug Administration.

Guiding Difficult Decisions on Scarce Investigational Therapeutic Agents in the COVID-19 Pandemic

The article “Ethically Allocating COVID-19 Drugs via Pre-Approval Access and Emergency Use Authorization” by Webb et al. (2020) provides a logical approach to allocating scarce investigational drugs via pre-approval access and emergency use authorization.

Ethical Issues in COVID-19 Pandemic

The ethical issues raised during the COVID-19 pandemic, which affected patients, health care provider and health care systems are discussed and some ethical solutions to these issues are provided.

Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

This study highlights the willingness of oncologists at a major cancer center to pursue non-trial access to experimental treatments for patients while also shedding light on the factors they use when considering such treatment.

Making Compassionate Use More Useful: Using real-world data, real-world evidence and digital twins to supplement or supplant randomized controlled trials

Real-world data real-world evidence as increasingly useful substitutes for data collected via RCTs, including the ethical, legal and social implications thereof are looked to and the use of digital twins is suggested as an additional method to derive causal inferences from real- world trials involving expanded access patients.

The Inherent Unfairness of COVID-19 Drug Access Pathways

A novel process regarding how to prioritize the allocation of COVID-19 drugs via emergency use authorization (EUA) and pre-approval access (PAA) pathways such as Expanded...

Pandemic Ethics and Status Quo Risk

This paper argues that public health institutions and public discourse alike have been misled by status quo bias-exaggerating the moral significance of the risks inherent in medical interventions, while systematically neglecting the (objectively greater) risk inherent in the status quo prospect of an out-of-control pandemic.

Physicians’ Ethical and Professional Obligations about Right-to-Try Amidst a Pandemic

A prioritization framework for unapproved drugs through preapproval pathways and clinical trials is proposed, arguing that patients seeking access should receive lower priority than approved drugs.

The Limits of Individualism: Potential Societal Harms from the EAP for Convalescent Plasma

  • D. Magnus
  • Sociology
    The American journal of bioethics : AJOB
  • 2020
This issue features a set of articles addressing allocation issues for drugs for COVID-19 that have not been approved by the FDA but are available through either Emergency Use Authorization or Expa...

References

SHOWING 1-10 OF 37 REFERENCES

An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US.

As researchers and drug manufacturers work tirelessly to find effective treatments for coronavirus disease 2019 (COVID-19), the media and the public await any report of a promising therapy, but little information is available about rationing of new therapies.

A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge.

This approach could simultaneously accomplish fair allocation and rapid learning, because the lottery creates a natural experiment that achieves random allocation in which some patients receive the drug while others do not; researchers can use the lottery’s registry to assess the effectiveness of the scarce drug.

Ethical Challenges Arising in the COVID-19 Pandemic: An Overview from the Association of Bioethics Program Directors (ABPD) Task Force

This paper discusses resource allocation and several related ethical challenges to the healthcare system and society, including how to define benefit, how to handle informed consent, the special needs of pediatric patients,How to engage communities in these difficult decisions, and how to mitigate concerns of discrimination and the effects of structural inequities.

Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials

This paper reports on a novel collaboration between a pharmaceutical company and an academic medical ethics department that led to the formation of the Compassionate Use Advisory Committee (CompAC), which established an ethical framework for the allocation of a scarce investigational oncology agent to single patients requesting non-trial access.

Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.

This Viewpoint reviews the FDA's May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug

Former FDA leaders decry emergency authorization of malaria drugs for coronavirus

The recent Food and Drug Administration (FDA) emergency use authorization for two malaria drugs to treat COVID-19 has jeopardized research to learn the drugs’ real value against the pandemic coronavirus, say former agency executives under President Donald Trump and former President Barack Obama.

Missed Opportunities on Emergency Remdesivir Use.

A decision to grant an EUA for remdesivir followed the release of a summary interim finding of shorter time to recovery among patients treated with the drug in a National Institute of Allergy and Infectious Diseases–funded phase 3 placebo-controlled clinical trial, but deeper concerns exist.

Patients’ Responsibilities in Medical Ethics

It is argued that certain duties of patients counterbalance an otherwise unfair captivity of doctors as helpers and that vulnerability does not exclude obligation.

Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.

Despite much resistance and controversy regarding asking patients with EVD to participate in a randomized clinical trial (RCT), the National Institutes of Health conducted the first and only RCT during that outbreak; however, it was too late for the RCT to be completed.